Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything

Area of Science:

• Oncology
• Medical Research

Background:

• Triple-negative breast cancer (TNBC) is aggressive and heterogeneous.
• TNBC is defined by the absence of oestrogen/progesterone receptors and HER2 expression.
• Current therapeutic strategies for TNBC are limited, leading to poor prognosis.

Purpose of the Study:

• To review emerging therapeutic targets and specific therapies for TNBC.
• To discuss available and novel drugs, including immunotherapy, targeted therapy, and ADCs.
• To compare regulatory approvals by US and European authorities and outline future clinical trial perspectives.

Main Methods:

• Literature review of recent studies on TNBC therapeutics.
• Analysis of clinical trial data and drug approval information.
• Synthesis of information on novel biomarkers and molecular signatures.

Main Results:

• Identification of novel therapeutic targets and molecular signatures in TNBC.
• Evaluation of the efficacy and regulatory status of emerging TNBC drugs.
• Highlighting the shift towards precision medicine in TNBC treatment.

Conclusions:

• Precision medicine approaches, including immunotherapy, targeted therapy, and ADCs, are transforming TNBC treatment.
• Understanding regulatory differences is crucial for global drug accessibility.
• Ongoing clinical trials are vital for advancing TNBC care and improving patient outcomes.